Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms SPN-820 was well-tolerated with few adverse events SPN-820 is a novel, first-in-class intracellular modulator of mTORC1 for the treatment of depression Company to host webcast today at 4:30 p.m. ET to discuss the topline data Topline results from Phase 2b randomized double-blind placebo-controlled study of SPN-820 in adults with treatment-resistant depression expected first-half 2025 ROCKVILLE, Md., Oct. 17, 2024 (GLOBE NEWSWI ...

ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a webcast and conference call on Thursday, October 17, 2024, at 4:30 p.m. ET to review data from the open-label Phase 2a study of SPN-820 for the treatment of major depressive disorder. A live webcast with presentation slides will be ...

Ahead of ADHD Awareness Month, Busy is sharing her ADHD diagnosis and Qelbree® (viloxazine extended-release capsules) treatment story to empower women living with ADHD to advocate for their care. ADHD often presents differently in women than in men, which can make it more challenging to recognize in women and ultimately leaving them undiagnosed and untreated.1 ROCKVILLE, Md., Sept. 24, 2024 (GLOBE NEWSWIRE) -- In a continued collaboration with Supernus Pharmaceuticals, actress, author, podcaster, late-night ...

Simon Webb and Duncan Nicholls/OJO Images via Getty Images Investment Overview The last - and also the first - time I covered Supernus Pharmaceuticals (NASDAQ:SUPN) for Seeking Alpha was in November 2023. I gave the company's stock a "strong buy" rating - shares traded at $26 at the time - and at the time of writing they trade at a value of $30 - up ~15%. I own some stock in the company myself. At the end of last week, shares actually traded at $35 per share - up 35% since my note - however the market has b ...

Piper Sandler downgraded Supernus Pharmaceuticals Inc SUPN, saying that the anticipated surge in Qelbree prescriptions during the back-to-school season has not materialized as expected. "That has us rethinking our assumptions regarding the longer-term (LT) sales/volume growth trajectory of the product," the analyst adds. Qelbree (viloxazine) is indicated to treat attention deficit hyperactivity disorder in children and adults. In the second quarter of 2024, net sales of Qelbree increased 92% year over year ...

ROCKVILLE, Md., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, September 4, 2024, at 4:30 p.m. ET at the Encore Boston Harbor Hotel in Everett, Massachusetts. Investo ...

Supernus Pharmaceuticals (SUPN) closed the last trading session at $31.48, gaining 10.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $40.50 indicates a 28.7% upside potential. The average comprises four short-term price targets ranging from a low of $38 to a high of $43, with a standard deviation of $2.08. While the lowest estimate indicates an increase of 20.7% from the curren ...

财务数据和关键指标变化 - 总收入在2024年第二季度同比增长24%,达到1.683亿美元 [26][31] - 剔除Trokendi XR和Oxtellar XR的收入,2024年第二季度总收入同比增长32% [27][32] - 2024年前6个月总收入同比增长8%,达到3.12亿美元 [31] - 剔除Trokendi XR和Oxtellar XR的收入,2024年前6个月总收入同比增长22% [32] - 2024年全年总收入预计在6亿到6.25亿美元之间,高于之前的5.8亿到6.2亿美元 [39] - 2024年全年GAAP经营利润预计在0到2000万美元之间,非GAAP经营利润预计在1亿到1.25亿美元之间 [40] 各条业务线数据和关键指标变化 - Qelbree处方量在2024年第二季度同比增长26%,达到184,342个,销售额同比增长92%,达到5900万美元 [11][13] - 2024年前6个月Qelbree处方量同比增长28%,销售额同比增长84%,达到1.05亿美元 [12] - Qelbree毛利率在2024年第二季度优于公司50%到55%的目标区间,预计全年将在45%到50%之间 [13][14] - GOCOVRI销售额在2024年第二季度同比增长10%,达到3200万美元 [15][16] - Oxtellar XR销售额在2024年第二季度同比增长25%,达到3000万美元 [17] - Trokendi XR销售额在2024年第二季度同比下降12%,达到1700万美元,预计全年将进一步下降 [17][18][19] 各个市场数据和关键指标变化 - 成人患者占Qelbree处方量的32% [14] - 成人患者的平均处方价格约为600-615美元,儿童患者为525美元,成人价格高出15%-17% [72] - 公司目前在成人ADHD市场占有率约为0.3%,在儿童市场占有率约为2% [79] - 公司预计Qelbree未来可达到4%-5%甚至10%的ADHD总市场份额 [79] 公司战略和发展方向及行业竞争 - 公司正积极推进SPN-817治疗难治性癫痫和SPN-820治疗难治性抑郁症的临床试验 [21][22][23][24] - 公司计划启动SPN-443治疗ADHD和其他中枢神经系统疾病的1期临床试验 [25] - 公司正在寻求战略机会,进一步加强在中枢神经系统疾病领域的未来增长和领导地位 [25] - 公司预计Trokendi XR和Oxtellar XR的全年销售额将在1.35亿到1.45亿美元之间 [19] - 公司对SPN-830获批持谨慎乐观态度,正等待FDA在几周内确定审评时间 [20] 管理层对经营环境和未来前景的评论 - 公司对Qelbree在成人和儿童市场的长期增长潜力保持乐观 [59][79] - 公司预计2024年ADHD市场整体增长将好于2023年 [56][57] - 公司有信心Qelbree的毛利率长期将维持在45%-50%的水平 [62][63] - 公司认为SPN-817和SPN-820的临床试验结果将在未来6-12个月内产生重要进展 [21][22][23][24] 其他重要信息 - 公司现金、现金等价物和流动性投资总额为3.472亿美元,较2021年底增加了7600万美元 [37][38] - 公司过去18个月内从经营活动中获得约2亿美元现金流,财务状况良好,无债务,为潜在并购和其他增长机会提供了灵活性 [38] 问答环节重要的提问和回答 问题1 **Andrew Tsai 提问** 对于SPN-830再次提交NDA,公司对获批的信心程度如何 [42] **Jack Khattar 回答** 公司与FDA进行了沟通,对本次重新提交的NDA较为有信心,预计很快就能获得FDA的审评时间安排 [43][44][45] 问题2 **David Amsellem 提问** 对于Qelbree在2024年下半年的增长预期,是否主要来自于处方量增长还是毛利率改善 [52][53][54] **Jack Khattar 回答** Qelbree的增长不仅来自毛利率改善,处方量增长也保持了20%以上的强劲势头,公司对产品长期增长潜力保持乐观 [55][59][60] 问题3 **Stacy Ku 提问** 公司对Qelbree全年2亿到2.2亿美元的销售目标有何评论,是否可能超出这一范围 [66][67] **Jack Khattar 回答** 公司对这一目标区间感到很有信心,如果今年的开学季表现强劲,有望接近甚至超出目标区间上限 [69]

For the quarter ended June 2024, Supernus Pharmaceuticals (SUPN) reported revenue of $168.33 million, up 24.2% over the same period last year. EPS came in at $0.36, compared to -$0.02 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $148.8 million, representing a surprise of +13.12%. The company delivered an EPS surprise of -2.70%, with the consensus EPS estimate being $0.37. While investors closely watch year-over-year changes in headline numbers -- revenue and earn ...

Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.36 per share, missing the Zacks Consensus Estimate of $0.37 per share. This compares to loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -2.70%. A quarter ago, it was expected that this drugmaker would post earnings of $0.39 per share when it actually produced break-even earnings, delivering a surprise of -100%. Over the last four quarters, th ...